9/15/14 - New indication for VIMPAT lacosamide: UCB's anti-epileptic drug approved by FDA as monotherapy in the treatment of patients with partial-onset... New indication for VIMPAT lacosamide: UCB's anti-epileptic drug approved by FDA as ... Pharmacy Choice, 1 day ago
FDA Okays Lacosamide Monotherapy in Partial-Onset Seizures - Diabetes Care, 2 weeks ago
New Indication for Anti-Epileptic Drug Lacosamide (Vimpat) - Pharmscope, 2 weeks ago
Human medicines European public assessment report (EPAR): Vimpat, lacosamide, Revision: 15, Authorised
This is a summary of the European public assessment report (EPAR) for Vimpat. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and ...European Medicines Agency, 1 month ago
Patent Application Titled "A Pharmaceutical Composition Comprising the Phytocannabinoids Cannabidivarin (Cbdv) and Cannabidiol (Cbd)" Published Online
By a News Reporter-Staff News Editor at Biotech Week -- According to news reporting originating from Washington, D.C. , by NewsRx journalists, a patent application by the inventors Whalley, Benjamin (Reading, GB); Williams, Claire (Reading, GB); ...4 Traders, 6 days ago Court Report - July 2014 #3 JD Supra, 1 month ago Global Epilepsy Therapeutics Market: Industry Analysis, Size, Share, Growth and Forecast 2019 Wall Street Select, 1 month ago
Epileptic seizures affect approximately 3 million Americans; many of them have their seizures well controlled by medication; however, some continue to suffer from seizures despite treatment . This severely impacts their quality of life. Now, a new ...Examiner.com, 1 week ago Fish Oil May Ease Tough-To-Treat Epilepsy, University of California, Los Angeles (UCLA) Study BioSpace, 1 week ago Low-doses of fish oil may reduce seizures in patients with drug-resistant epilepsy Noodls, 1 week ago
Oncology/Hematology Published: Sep 3, 2014 ByMedPage Today Staff No survival benefit was seen with double mastectomy in breast cancer patients, compared with breast-conserving surgery and radiotherapy, a JAMA study found . Sanofi's ...MedPage Today, 1 week ago
The drug perampanel (trade name Fycompa) has been approved since July 2012 as adjunctive ("add-on") therapy for adults and children aged 12 years and older with epileptic fits (seizures). In a new early benefit assessment according to the Act on the ...News-Medical.Net, 3 weeks ago Perampanel for epilepsy: Still no proof of added benefit EurekAlert!, 4 weeks ago Still no proof of added benefit for perampanel in epilepsy Medical News Today, 3 weeks ago
The Galien Foundation Announces 2014 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Agent," and "Best Medical Technology"
/PRNewswire/ -- The Galien Foundation today announced the 2014 nominees for the eighth annual Prix Galien USA Awards. The Prix Galien Award is considered the biomedical industry's highest accolade and recognizes the technical, scientific and ...TickerTech.com, 1 month ago
By Targeted News Service ALEXANDRIA, Va., July 17 -- Quest Diagnostics Investments, Wilmington, Delaware, has been assigned a patent (8,779,355) developed by four co-inventors for "methods for detecting lacosamide byFinancial Content, 2 months ago
Epilepsy Therapeutics in Asia Pacific Markets to 2019 - Treatment Options Enhanced As Novel Next Generation AEDs Show Improved Safety and Tolerability
/PRNewswire/ -- Reportbuyer.com has added a new market research report: Summary GBI Research, the leading business intelligence provider, has released its latest research, " ", which provides in-depth analysis of epilepsy market within the ...MoneyShow.com, 2 months ago Epilepsy Therapeutics in Major Developed Markets to 2019 - New AEDs with Novel Mechanisms of Action Signal a Shift in Treatment Patterns TVNewsCheck, 2 months ago
on your WebpageAdd Widget >Get your members hooked!